Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

• Published in: Biological psychiatry (1969) Vol. 83; no. 4; pp. 311 - 319
• Main Author: van Dyck, Christopher H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.02.2018
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - therapy; Alzheimer’s disease; Amyloid beta-Peptides - immunology; Amyloid-related imaging abnormalities; Amyloid-β; Amyloid-β oligomers; Antibodies, Monoclonal - therapeutic use; Humans; Immunotherapy; Immunotherapy - methods; Middle Aged; Monoclonal antibodies; Psychiatric/Mental Health; Amyloid-β oligomers; Monoclonal antibodies; Amyloid-β; Alzheimer’s disease; Amyloid-related imaging abnormalities; Immunotherapy

The majority of putative disease-modifying treatments in development for Alzheimer’s disease are directed against the amyloid-β (Aβ) peptide. Among the anti-Aβ therapeutic approaches, the most extensively developed is immunotherapy—specifically, passive immunization through administration of exogeno...